Abstract CT162: The phase 1b PORTIA study: Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL)

2020 ◽  
Author(s):  
Ulrich Jaeger ◽  
Nina Worel ◽  
Joseph P. McGuirk ◽  
Peter A. Riedell ◽  
Isabelle Fleury ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Safety And Efficacy ◽  
Large B Cell Lymphoma ◽  
Phase 1B ◽  
Large B Cell

Safety and efficacy of CHOP for treatment of diffuse large B-cell lymphoma with different cART regimens: SCULPT study

2013 ◽  
Vol 18 (5) ◽  
pp. 699-707 ◽  
Author(s):  
Alison YJ Wong ◽  
Suzanne Marcotte ◽  
Mathieu Laroche ◽  
Nancy L Sheehan ◽  
Vishal Kukreti ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Safety And Efficacy ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study

2019 ◽  
Vol 20 (7) ◽  
pp. 998-1010 ◽  
Author(s):  
Hervé Tilly ◽  
Franck Morschhauser ◽  
Nancy L Bartlett ◽  
Amitkumar Mehta ◽  
Gilles Salles ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Open Label ◽  
Large B Cell Lymphoma ◽  
Phase 1B ◽  
Large B Cell
Sign in / Sign up

Export Citation Format

Share Document